Clinical Trial Update: Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant chemoradiation combined with serplulimab in locally advanced gastroesophageal junction adenocarcinoma; efficacy and safety …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN